543 related articles for article (PubMed ID: 31054006)
1. Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?
Martinez Chanza N; Tripathi A; Harshman LC
Curr Treat Options Oncol; 2019 May; 20(5):44. PubMed ID: 31054006
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis.
Sun M; Marconi L; Eisen T; Escudier B; Giles RH; Haas NB; Harshman LC; Quinn DI; Larkin J; Pal SK; Powles T; Ryan CW; Sternberg CN; Uzzo R; Choueiri TK; Bex A
Eur Urol; 2018 Nov; 74(5):611-620. PubMed ID: 29784193
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant treatment for renal cell carcinoma: do we finally have a major breakthrough?
Patel DN; Figlin RA; Kim HL
Clin Adv Hematol Oncol; 2016 Nov; 14(11):907-914. PubMed ID: 27930642
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials.
Lenis AT; Donin NM; Johnson DC; Faiena I; Salmasi A; Drakaki A; Belldegrun A; Pantuck A; Chamie K
J Urol; 2018 Jan; 199(1):43-52. PubMed ID: 28479237
[TBL] [Abstract][Full Text] [Related]
5. The Changing Landscape of Management of Metastatic Renal Cell Carcinoma: Current Treatment Options and Future Directions.
Salgia NJ; Dara Y; Bergerot P; Salgia M; Pal SK
Curr Treat Options Oncol; 2019 Apr; 20(5):41. PubMed ID: 30937639
[TBL] [Abstract][Full Text] [Related]
6. The current role for adjuvant and neoadjuvant therapy in renal cell cancer.
Gleeson JP; Motzer RJ; Lee CH
Curr Opin Urol; 2019 Nov; 29(6):636-642. PubMed ID: 31348025
[TBL] [Abstract][Full Text] [Related]
7. The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?
Patel HD; Puligandla M; Shuch BM; Leibovich BC; Kapoor A; Master VA; Drake CG; Heng DY; Lara PN; Choueiri TK; Maskens D; Singer EA; Eggener SE; Svatek RS; Stadler WM; Cole S; Signoretti S; Gupta RT; Michaelson MD; McDermott DF; Cella D; Wagner LI; Haas NB; Carducci MA; Harshman LC; Allaf ME
Future Oncol; 2019 May; 15(15):1683-1695. PubMed ID: 30968729
[TBL] [Abstract][Full Text] [Related]
8. Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma.
Xu W; Puligandla M; Manola J; Bullock AJ; Tamasauskas D; McDermott DF; Atkins MB; Haas NB; Flaherty K; Uzzo RG; Dutcher JP; DiPaola RS; Bhatt RS
Clin Cancer Res; 2019 Oct; 25(20):6098-6106. PubMed ID: 31471309
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature.
Bandini M; Smith A; Marchioni M; Pompe RS; Martel TF; Cindolo L; Montorsi F; Shariat SF; Briganti A; Kapoor A; Capitanio U; Karakiewicz PI
Clin Genitourin Cancer; 2018 Jun; 16(3):176-183. PubMed ID: 29449091
[TBL] [Abstract][Full Text] [Related]
10. Systemic therapy in the management of localized and locally advanced renal cell carcinoma: Current state and future perspectives.
Berquist SW; Yim K; Ryan ST; Patel SH; Eldefrawy A; Cotta BH; Bradshaw AW; Meagher MF; Bindayi A; McKay RR; Autorino R; Staehler M; Derweesh IH
Int J Urol; 2019 May; 26(5):532-542. PubMed ID: 30943578
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.
Coppin C; Kollmannsberger C; Le L; Porzsolt F; Wilt TJ
BJU Int; 2011 Nov; 108(10):1556-63. PubMed ID: 21952069
[TBL] [Abstract][Full Text] [Related]
12. Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma.
Fukuda T; Kamai T; Masuda A; Nukui A; Abe H; Arai K; Yoshida K
Cancer Med; 2016 Aug; 5(8):1810-20. PubMed ID: 27292320
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant therapy in renal cell carcinoma: is resection still solely enough?
Gharib KE
Future Oncol; 2021 Feb; 17(6):633-636. PubMed ID: 33305597
[No Abstract] [Full Text] [Related]
15. Adjuvant therapy in renal cell carcinoma.
Gul A; Rini BI
Cancer; 2019 Sep; 125(17):2935-2944. PubMed ID: 31225907
[TBL] [Abstract][Full Text] [Related]
16. Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial.
Patel A; Ravaud A; Motzer RJ; Pantuck AJ; Staehler M; Escudier B; Martini JF; Lechuga M; Lin X; George DJ
Clin Cancer Res; 2020 Sep; 26(18):4863-4868. PubMed ID: 32546645
[TBL] [Abstract][Full Text] [Related]
17. The emerging role of targeted therapy in renal cell carcinoma (RCC): is it time for a neoadjuvant or an adjuvant approach?
Sciarra A; Cattarino S; Salciccia S; Alfarone A; Gentilucci A; Parente U; Mariotti G; Innocenzi M; Gentile V
Crit Rev Oncol Hematol; 2012 Feb; 81(2):151-62. PubMed ID: 21388825
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant therapy for renal cell carcinoma.
Haas NB; Uzzo R
Curr Oncol Rep; 2008 May; 10(3):245-52. PubMed ID: 18765155
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis.
Harshman LC; Xie W; Moreira RB; Bossé D; Ruiz Ares GJ; Sweeney CJ; Choueiri TK
Cancer; 2018 Mar; 124(5):925-933. PubMed ID: 29266178
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant therapy for high-risk renal cell carcinoma after nephrectomy how many trials are positive? Only one or more than one.
Ravaud A
Asia Pac J Clin Oncol; 2020 Sep; 16 Suppl 3():12-17. PubMed ID: 32852898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
